Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Session 3 – Molecular Targets in TNBC Disease – TILs, PDL1 and Ki 67

Update on the Clinical Efficacy of Targeted Agents: Indications, Efficacy and Toxicity

Date

09 Jun 2023

Session

Session 3 – Molecular Targets in TNBC Disease – TILs, PDL1 and Ki 67

Topics

Targeted Therapy

Tumour Site

Breast Cancer

Presenters

B. Pistilli, FR

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.